Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Antibodies that Modulate TGFß Activation
Scholar Rock Holding Corporation (SRRK)
Last scholar rock holding corporation earnings: 11/12 07:30 am
Check Earnings Report
Company Research
Source: Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the United States Patent Office (USPTO) issued U.S. Patent No. 10,597,443 with an expiry of May 2034. This patent broadly covers methods for making activation modulators of TGFß that utilize Scholar Rock’s proprietary platform approach of targeting the precursor form of growth factors.“We are pleased with this important addition to our patent portfolio as it further differentiates our leadership position in the development of antibodies that modulate signaling of TGFß isoforms,” said Nagesh Mahanthappa, Ph.D., President and CEO of Scholar Rock. “TGFß is a key driver of a number of disease-relevant processes, including fibrosis and immune system evasion by cancer cells, for which we have discovered highly potent and selective inhibitors of TGFß1 activation
Show less
Read more
Impact Snapshot
Event Time:
SRRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRRK alerts
High impacting Scholar Rock Holding Corporation news events
Weekly update
A roundup of the hottest topics
SRRK
News
- Scholar Rock (SRRK) valuation after FDA manufacturing update and apitegromab resubmission plans [Yahoo! Finance]Yahoo! Finance
- Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]Seeking Alpha
- Scholar Rock (NASDAQ:SRRK) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.MarketBeat
- Scholar Rock (NASDAQ:SRRK) had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $47.00. They now have an "overweight" rating on the stock.MarketBeat
- Scholar Rock (NASDAQ:SRRK) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $42.00 price target on the stock.MarketBeat
SRRK
Earnings
- 11/14/25 - Miss
SRRK
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- 12/2/25 - Form 8-K
- SRRK's page on the SEC website